Are Options Traders Betting on a Big Move in CONMED Stock?

The May 15, 2026 $80 call on CONMED registered among the highest implied volatilities, signaling options traders expect a sizable move in the stock. Analysts cut the current-quarter EPS consensus from $0.93 to $0.82 (down $0.11, -11.8%) over the past 60 days; Zacks rates CNMD a #3 (Hold) in an industry ranked in the top 22%. Two analysts lowered estimates and none raised them. Elevated IV presents potential premium-selling opportunities but also indicates higher short-term volatility risk to the equity.

Analysis

The long-dated one‑sided option flow and steep call skew look like a concentrated directional wager (M&A or a single‑buyer directional trade) rather than broad, event-driven hedging. That structure elevates risk for premium sellers because gamma concentration can force rapid repricing on an intraday gap; conversely, if no binary arrives, that same skew is likely to mean‑revert and create a predictable premium decay opportunity over the next 3–9 months.

Analyst cut activity and weaker near‑term estimates imply an earnings drift that favors downside or sideways outcomes absent a clear catalyst; this makes short volatility attractive on a calendar‑adjusted basis but increases tail risk to the upside if a takeover or surprise commercial win materializes. Time horizons split cleanly: days–weeks for gamma squeezes around any visible rumor/print, months for IV reversion and premium capture, and 12–24 months if underlying margin pressure becomes structural.

Second‑order winners from a CNMD downside outcome include larger OEMs and consumables platforms that can absorb procedure volume declines with scale (they will see relatively stable margins), while small component/single‑product suppliers lose pricing power and get pushed into inventory destocking. If the market is pricing a takeover, the acquirer set is important — strategic buyers would re‑price supplier contracts and distribution deals, creating a re‑valuation pathway for adjacent small caps.

Execution discipline matters: treat any short‑vol position as “time arbitrage,” size small, and build in explicit IV and price stop triggers. Monitor block trade prints, institutional 13F changes, and the options position concentration (top 10 buyers/sellers) — a persistent single‑buyer footprint increases short squeeze tail risk and should change sizing and hedge choice immediately.

Key Decisions for Investors

• Income trade (defined risk): Sell CNMD May‑15‑2026 80/90 call spread (15‑pt width). Size = 1–2% of NAV. R/R = collect premium today; target 25–40% of max profit within 3–6 months if IV drifts down; max loss = $15 − credit. Kill‑switch: close/flip if CNMD > 95 or IV jumps >20% on a single session.
• Hedge/pair (fundamental relative value): Short CNMD equity vs long SYK (or MDT) equal notional, horizon 3–9 months. Rationale = capture asymmetric downside tied to company‑specific estimate cuts while keeping exposure to healthcare equipment beta. Position size = small (0.5–1% net short CNMD); stop if CNMD outperforms peer by >15% on positive catalyst.
• Volatility derail (protect downside): Buy one May‑15‑2026 CNMD put (e.g., 60 strike) as crash insurance for any long exposure; cap cost to 1–2% of portfolio. This preserves upside optionality while limiting downside risk from a surprise negative binomial event over 12+ months.
• Covered‑income contrarian: If conviction in takeover rumor rises after confirming block trades, buy CNMD stock and sell the May‑15‑2026 80 call (covered). Aim to harvest elevated long‑dated premium while capping position size to 1% of NAV; unwind if a formal bid appears or implied takeover arithmetic changes materially.